Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 791

Sort by

Sort Order Select

Journal Articles

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Blood blood.2025030149.

https://doi.org/10.1182/blood.2025030149

Published: 2025

Includes: Supplemental data

Journal Articles

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panos Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Dr, Foteini Theodorakakou, Vasiliki Spiliopoulou, Irene Solia, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Blood blood.2025031629.

https://doi.org/10.1182/blood.2025031629

Published: 2025

Includes: Supplemental data

Journal Articles

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Eduardo Edelman Saul, Jessie Xu, Casey Bermack, Cathrine Paras, Jared Henderson, Kristofer Jennings, Bryan Valcarcel, Dr. Mohammad Abdul-Jaber Abdulla, Luis Fayad, Hun Lee, Preetesh Jain, Ranjit Nair, Michael Wang, Swami Iyer, Christopher Flowers, Luis Malpica

Blood (2025) 146 (Supplement 1): 5422.

https://doi.org/10.1182/blood-2025-5422

Published: 2025

Journal Articles

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Hishan Tharmaseelan, Sarah Gillessen, Ina Bühnen, Carsten Kobe, Karin G. Schrenk, Prof. Dr. Max S Topp, Ulf Schnetzke, Nico Freund, Stephanie Sasse, Philipp Ernst, Tanja Zamrik, Wolfram Klapper, Michael Fuchs, Sven Borchmann, Paul Bröckelmann, Peter Borchmann, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2025-5401

Published: 2025

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Mika Kontro, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Amer Zeidan, Naval Daver

Blood (2025) 146 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2025-5627

Published: 2025

Journal Articles

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience

Vijaykumar Shirure, Velu Nair, Dr. Sandipkumar Kheni, Dhara Shah, Neha Motwani, Chaitrangi Rohekar, Grishma Sukhwal, Yoshaan Joshi, Raj Gabani

Blood (2025) 146 (Supplement 1): 7138.

https://doi.org/10.1182/blood-2025-7138

Published: 2025

Journal Articles

pediatric transplant data from a center in a remote area in interior sindh, Pakistan

Dr Asghar Ali, Muhammad Sarwar, Dr Hafiz Muhammad Nadeem Arain, Uzair Ahmad, Muhammad Afzal, Parvez Ahmed

Blood (2025) 146 (Supplement 1): 7727.

https://doi.org/10.1182/blood-2025-7727

Published: 2025

Journal Articles

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Prof. Dr. Max S Topp, Guoqing Wang, Puja Patel, Rushdia Yusuf, David Lavie

Blood (2025) 146 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2025-5480

Published: 2025

Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood (2025) 146 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2025-2282

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Daniel Wiseman, Jak Laight, Rebecca Boucher, Chhaya Sankhalpara, Rebecca Record, Jennifer Byrne, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Srinivasan Narayanan, Rob Sellar, Kiran Batta, Manoj Raghavan, Dr. Emma Searle, Catherine Cargo, Steve Knapper, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 488.

https://doi.org/10.1182/blood-2025-488

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Journal Articles

Impact of pre- and post-transplant transfusion requirements on outcomes in severe aplastic anemia patients

Uzair Ahmad, Parvez Ahmed, Muhammad Afzal, Dr Asghar Ali, Muhammad Sarwar, Saba Aslam, Faiza Shaikh, Kantaish Chawla

Blood (2025) 146 (Supplement 1): 7740.

https://doi.org/10.1182/blood-2025-7740

Published: 2025

Journal Articles

MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease

Alison Maloney, Gilbert Ansa, Graham Craggs, Gillian Farnie, Matthew Fawkes, Fenella Gross, Joe Harman, Sarah Major, Thomas Milne, Ryan Robinson, Dr. Emma Searle, Iain Simpson, Alastair Smith, Tim Somervaille, John Pollard

Blood (2025) 146 (Supplement 1): 320.

https://doi.org/10.1182/blood-2025-320

Published: 2025

Journal Articles

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Johannes Duell, Diana Alvarez Arias, Wolfram Klapper, Sarah Reinke, Florian Eisele, Thomas Larsen, Prof. Dr. Max S Topp, Beth Rumberger, TaeHyung (Simon) Kim, Andreas Rosenwald, Hilka Rauert-Wunderlich

Blood (2025) 146 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2025-5515

Published: 2025

Journal Articles

Epidemiology, risk factors, and outcomes of cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplantation: A retrospective observational single-centre study from western India

Dr. Sandipkumar Kheni, Velu Nair, Vijaykumar Shirure, Dhara Shah, Neha Motwani, Grishma Sukhwal, Chaitrangi Rohekar, Yoshaan Joshi, Raj Gabani

Blood (2025) 146 (Supplement 1): 7751.

https://doi.org/10.1182/blood-2025-7751

Published: 2025

Journal Articles

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Catherine Thieblemont, Martin Hutchings, Prof. Dr. Max S Topp, Won-Seog Kim, Dai Maruyama, Azadeh Shohoudi, Robin Lesley, Wendy Chang, Marlene Zuraek, Mihail Obrocea, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2025-3747

Published: 2025

Journal Articles

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Mika Kontro, Naval Daver

Blood (2025) 146 (Supplement 1): 236.

https://doi.org/10.1182/blood-2025-236

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience

pediatric transplant data from a center in a remote area in interior sindh, Pakistan

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Impact of pre- and post-transplant transfusion requirements on outcomes in severe aplastic anemia patients

MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Epidemiology, risk factors, and outcomes of cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplantation: A retrospective observational single-centre study from western India

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only